Veritable, L.P. Apellis Pharmaceuticals, Inc. Transaction History

Veritable, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$76.68 - $93.31 $10,735 - $13,063	-140 Reduced 3.8%	3,543 $322,000
Q1 2023 May 12, 2023	BUY	$46.59 - $66.96 $171,590 - $246,613	3,683 New	3,683 $242,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $158,584 - $246,805	3,543 New	3,543 $242,000
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $111,250 - $247,443	-3,543 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $144,908 - $229,940	3,543 New	3,543 $224,000
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $144,554 - $203,332	-3,543 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$30.79 - $57.2 $109,088 - $202,659	3,543 New	3,543 $203,000

302

123M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.65B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Veritable, L.P., based on Form 13F filings with the SEC.

Stay updated on Veritable, L.P. with notifications on news.